447% Return In 2 Yrs! THIS Specialty Chemical Stock Ends Higher After Acquisition Update | Do You Own?

Sudarshan Pharma Industries Limited shares ended higher on Thursday, June 11, after the integrated pharmaceutical and specialty chemicals firm announced the incorporation of a new wholly-owned subsidiary, Sudarshan Industries in the United States.

The stock ended 0.2% higher at Rs 35.07 per share on BSE with a market capitalisation of Rs 843.99 crore on Thursday. The stock has delivered 447% return in two years.

Sudarshan Pharma Industries Ltd, an integrated pharmaceutical and specialty chemicals company with a market capitalization of ₹842.31 crore, has announced the incorporation of a new wholly-owned subsidiary, Sudarshan Industries Inc. (Sudarshan USA), in the United States.

According to the company's exchange filing, Sudarshan USA was registered in Delaware on June 5, 2026. The subsidiary will focus on the manufacturing, import, export, wholesale, and retail of pharmaceuticals, medicines, antibiotics, healthcare products, nutraceuticals, Ayurvedic products, vaccines, Active Pharmaceutical Ingredients (APIs), and specialty chemicals.

Sudarshan Pharma has subscribed to 1,00,00,000 shares of the new entity with a face value of US$0.00001 per share, representing a total investment of US$100. This investment grants the company a 100% stake in the subsidiary. The move is intended to broaden the company's customer base and business operations within the US market. The investment funds will be remitted following necessary approvals under Reserve Bank of India (RBI) regulations.

Financial Performance
In the March quarter, Sudarshan Pharma reported a 44.80% increase in profit to ₹10.73 crore, up from ₹7.41 crore in the corresponding quarter of the previous year. Sales grew by 36.72% to ₹220.92 crore, compared to ₹161.59 crore in the same period a year ago.

For the full fiscal year 2026, net profit rose by 55.64% to ₹233 million, compared to ₹149.7 million in the previous year. Annual sales increased by 39.21% to ₹703.06 million, compared to ₹505.04 million in the prior year.

According to BSE Analytics, the stock has yielded a return of 437.63% over three years and 446.88% over two years. On a year-to-date basis, it has gained 29.49%. The stock hit a 52-week high of ₹36.95 on May 27, 2026, and a 52-week low of ₹18.50 on January 29, 2026.

Market Overview
Stock market benchmark indices, Sensex and Nifty, declined in early trade on Thursday, tracking weak global trends, rising crude oil prices, and escalating tensions between the US and Iran. Persistent foreign fund outflows and rising US inflation also dampened market sentiment.

The 30-share BSE Sensex declined 358.54 points to 73,624.64, while the 50-share NSE Nifty dropped 117 points to 23,098.30. Among the Sensex firms, HCL Tech, Infosys, Tech Mahindra, Tata Consultancy Services, and Trent were among the laggards, while Power Grid, ICICI Bank, Bharti Airtel, and InterGlobe Aviation saw gains.

Brent crude, the global oil benchmark, traded 1.70% higher at USD 94.68 per barrel. According to exchange data, Foreign Institutional Investors (FIIs) offloaded equities worth ₹2,124.98 crore on Wednesday.

"Fresh military action by the United States against Iranian targets has reignited concerns over the stability of the Middle East, raising fears that recent diplomatic efforts may be losing momentum and increasing the risk of a broader regional conflict," said Ponmudi R, CEO of Enrich Money.